Spots Global Cancer Trial Database for haploidentical stem cell transplantation

Every month we try and update this database with for haploidentical stem cell transplantation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias	NCT02759822	Leukemia, Myelo... Precursor Cell ...	Haploidentical ...	1 Year - 60 Years	Instituto Nacional de Cancer, Brazil
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor	NCT00967343	Myeloid Leukemi... Lymphoblastic L... Lymphoma Multiple Myelom... Myelodysplastic... Myeloproliferat...	Donor lymphocyt...	18 Years - 65 Years	Kiadis Pharma
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor	NCT00967343	Myeloid Leukemi... Lymphoblastic L... Lymphoma Multiple Myelom... Myelodysplastic... Myeloproliferat...	Donor lymphocyt...	18 Years - 65 Years	Kiadis Pharma
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor	NCT02500550	Acute Myeloid L... Acute Lymphobla... Myelodysplastic...	ATIR101 Haploidentical ... TBI regime Non-TBI regime	18 Years - 65 Years	Kiadis Pharma
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies	NCT02566395	Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Chronic Myeloge... Non-Hodgkin Lym... Hodgkin Lymphom...	Radiation Cyclophosphamid... Donor Lymphocyt... Haploidentical ...	2 Years - 21 Years	Northwell Health
Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias	NCT02759822	Leukemia, Myelo... Precursor Cell ...	Haploidentical ...	1 Year - 60 Years	Instituto Nacional de Cancer, Brazil
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer	NCT02999854	Acute Myeloid L... Acute Lymphobla... Myelodysplastic...	ATIR101 Cyclophosphamid... T-cell depleted... T-cell replete ...	18 Years - 70 Years	Kiadis Pharma
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide	NCT03088709	Acute Myeloid L... Acute Lymphocyt... Myelodysplastic... Non-hodgkin Lym... Chronic Lymphoc...	Cyclophosphamid... Tacrolimus Mycophenolate m... Haploidentical ...	16 Years - 90 Years	Loyola University
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies	NCT02566395	Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Chronic Myeloge... Non-Hodgkin Lym... Hodgkin Lymphom...	Radiation Cyclophosphamid... Donor Lymphocyt... Haploidentical ...	2 Years - 21 Years	Northwell Health
Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours	NCT01337544	Childhood Solid...	HAPLOIDENTICAL ...	6 Months - 22 Years	Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Haploidentical Stem Cell Transplantation in Neuroblastoma	NCT00790413	Neuroblastoma	iodine I 131 me... Fludarabine Thiotepa T-cell depletio... Haploidentical ... Donor Lymphocyt... Rituximab Co-transplantat...	6 Months - 21 Years	Lund University Hospital
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor	NCT02500550	Acute Myeloid L... Acute Lymphobla... Myelodysplastic...	ATIR101 Haploidentical ... TBI regime Non-TBI regime	18 Years - 65 Years	Kiadis Pharma
Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias	NCT02759822	Leukemia, Myelo... Precursor Cell ...	Haploidentical ...	1 Year - 60 Years	Instituto Nacional de Cancer, Brazil
Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours	NCT01337544	Childhood Solid...	HAPLOIDENTICAL ...	6 Months - 22 Years	Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML	NCT04002115	Acute Myeloid L...	Clofarabine Fludarabine Busulfan Total Body Irra... Cyclophosphamid... Granulocyte Col... Tacrolimus Cellcept	18 Years - 55 Years	Milton S. Hershey Medical Center
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor	NCT01794299	Acute Myeloid L... Acute Lymphobla... Myelodysplastic...	ATIR	18 Years - 65 Years	Kiadis Pharma
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML	NCT04002115	Acute Myeloid L...	Clofarabine Fludarabine Busulfan Total Body Irra... Cyclophosphamid... Granulocyte Col... Tacrolimus Cellcept	18 Years - 55 Years	Milton S. Hershey Medical Center
Haploidentical Stem Cell Transplantation in Neuroblastoma	NCT00790413	Neuroblastoma	iodine I 131 me... Fludarabine Thiotepa T-cell depletio... Haploidentical ... Donor Lymphocyt... Rituximab Co-transplantat...	6 Months - 21 Years	Lund University Hospital

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: